MedTrace Logo

Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).

NCT06419322 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-02-03

No results posted yet for this study

Summary

The goal of this study is to investigate the acceptability, feasibility, safety and efficacy of an optimized rehabilitation program for treated patients with spinal muscular atrophy (SMA) compared to the current rehabilitation program in the United Kingdom. The aim is to provide patients with more hands on physiotherapy and access to rehabilitation devices at home to support parents currently providing rehabilitation on their own.

Conditions

Interventions

OTHER

Optimized rehabilitation program

Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.

Sponsors & Collaborators

  • Oxford Brookes University

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • ACE SMA Charity

    collaborator UNKNOWN

  • Roche Products Limited

    collaborator UNKNOWN

  • Scholar Rock, Inc.

    collaborator INDUSTRY

  • Biohaven Therapeutics Ltd.

    collaborator INDUSTRY

  • Rally Round Rupert Charity

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Principal Investigators

  • Charlotte Lilien · University of Oxford, Department of Paediatrics

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06419322 on ClinicalTrials.gov